吉非替尼辅助治疗对中晚期NSCLC患者癌细胞凋亡及生存时间的影响  

Effects of gefitinib on cancer cell apoptosis and survival time of patients with advanced NSCLC

作　　者：贾同福[1] 

机构地区：[1]淄博市中心医院肿瘤一科,山东省淄博255036

出　　处：《中国医师杂志》2017年第10期1520-1523,共4页Journal of Chinese Physician

摘　　要：目的观察吉非替尼辅助治疗对中晚期非小细胞肺癌（NSCLC）患者癌细胞凋亡及生存时间的影响。方法选择2013年6月至2015年10月期间在本院确诊为NSCLC ⅢB—Ⅳ期的126例患者，随机分为接受AC方案化疗的A组、吉非替尼治疗的B组、AC方案化疗联合吉非替尼治疗的C组。观察随访三组患者12个月内的无进展生存（PFS）率以及客观缓解率（ORR），测定血清中肿瘤标志物的含量及肿瘤病灶中凋亡分子的mRNA表达量。结果C组患者的12个月ORR及PFS率均显著高于A组、B组，B组患者的12个月ORR及PFS率均显著高于A组。治疗后1个周期时，三组患者血清中癌胚抗原（CEA）、细胞角蛋白19片段（CYFRA21—1）、TK-1的含量均显著低于治疗前，肿瘤病灶中Caspase-3、Caspase-8、Caspase-9的mRNA表达量均显著高于治疗前；C组患者血清中CEA、CYFRA21—1、胸苷激酶-1（TK-1）的含量均显著低于A组、B组，肿瘤病灶中Caspase-3、Caspase．8、Caspase-9的mRNA表达量均显著高于A组、B组；B组患者血清中CEA、CYFRA21—1、TK-1的含量均显著低于A组，肿瘤病灶中Caspase-3、Caspase-8、Caspase-9的mRNA表达量均显著高于A组。结论吉非替尼联合静脉化疗能够延长晚期NSCLC患者的生存时间并杀伤肿瘤细胞、诱导细胞凋亡。Objective To study the effect of epidermal growth factor receptor-tyrosine kinase inhibitor （EGFR-TKI） gefitinib on cancer cell apoptosisand survival time of patients with advanced non-small cell lung cancer （NSCLC）. Methods A total of 126 cases of patients diagnosised as NSCLC stage ⅢB -Ⅳ in our hospital during June 2013-October 2015 were randomly divided into group A received AC chemo- therapy, group B received gefitinib, and group C received AC chemotherapy combined with gefitinib thera- py. The progression free survival （PFS） rate and objective response rate （ORR） were measured during 12 months follow-up, tumor markers contents in serum and the mRNA expression of apoptosis molecules in tumor lesions were measured. Results The 12-month ORR and PFS of group C were significantly higher than those in groups A and B. The 12-month ORR and PFS of group B were significantly higher than those in group A. For 1 cycle after treatment, serum carcinoembryonic antigen （CEA）, cytokeratin 19 （CY- FRA21-1 ） , and thymidine kinase-1 （TK-1） contents among three groups were significantly lower than those before treatment. Caspase-3, Caspase-8, and Caspase-9 mRNA expressions in tumor were significantly higher than those before treatment. For 1 cycle after treatment, serum CEA, CYFRA21-1, and TK-1 con- tents of group C were significantly lower than groups A and B. Caspase-3, Caspase-8, and Caspase-9 mRNA expressions in tumor were significantly higher than those groups A and B, and serum CEA, CYFRA21- 1, and TK-1 contents of group B were significantly lower than group A. Caspase-3, Caspase-8, and Caspase-9 mRNA expressions in tumor were significantly higher than thsoe of group A. Conclusions Gefitinib combined with intravenous chemotherapy can prolong the survival time of patients with advanced NSCLC and kill tumor cells, induce apoptosis.

关 键 词：喹唑啉类/投药和剂量 癌 非小细胞肺/药物疗法 细胞凋亡 存活率 

分 类 号：R734.2[医药卫生—肿瘤]